RxDoctor Payments Data

Steffany Mock, PA

Medical · San Antonio, TXNPI 1194996314

Payments from drug & device makers

$10,461in general payments, 2019–2025

Across 369 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Novo Nordisk$1K
  • AstraZeneca$724
  • Lilly USA, LLC$678
  • Corcept Therapeutics$573
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$10,39399%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,461 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$35,296
Medicare patients
140
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate24$22,403
FarxigaDapagliflozin Propanediol13$21,398
EliquisApixaban20$20,538
OzempicSemaglutide16$17,330
MyrbetriqMirabegron12$16,021
XareltoRivaroxaban21$14,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,164
DottiEstradiol24$3,437
SynthroidLevothyroxine Sodium28$3,185
Estradiol (Once Weekly)Estradiol19$1,735
Levothyroxine Sodium165$1,701
Estradiol19$1,691
Estradiol (Twice Weekly)Estradiol14$1,646
ProgesteroneProgesterone, Micronized53$1,252
Rosuvastatin Calcium165$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$56$22,40324 claims
AstraZenecaFarxiga$724$21,39813 claims
PfizerEliquis$15$20,53820 claims
Novo NordiskOzempic$1,005$17,33016 claims
Astellas Pharma US IncMyrbetriq$368$16,02112 claims
Johnson & JohnsonXarelto$1,114$14,79421 claims
GSKTrelegy Ellipta$235$12,16417 claims
AbbVieSynthroid$1,130$3,18528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →